Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual

Published
07 November 2018
By
Gus Cairns
Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds

A study measuring HIV drug resistance at two timepoints in Kenyan patients on second-line, protease inhibitor-based regimens has found very high levels of drug resistance in people with

Published
22 October 2018
By
Gus Cairns
Uganda:15 Percent HIV-Positive Ugandans Resistant to Drugs - Report

Nearly two in every 10 people living with HIV in Uganda are resistant to antiretroviral (ARVs) drugs, according to findings in a study report that Uganda Virus Research Institute (UVRI) released yesterday. This, the researchers said, requires them to switch to more expensive and scarce medicines.

Published
13 September 2018
From
AllAfrica
Ibalizumab Provides New Option for Patients with Multidrug-Resistant HIV

A newly published phase 3 study of patients with multidrug-resistant (MDR) HIV shows that ibalizumab can be a safe and effective option for patients with limited other avenues of treatment.

Published
23 August 2018
From
MD Magazine
New HIV therapy reduces virus, boosts immunity in drug-resistant patients

Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

Published
16 August 2018
From
Science Daily
Reported 'PrEP Failure' in Thailand May Be a Missed Acute HIV Infection: Here's What You Need to Know

The Infectious Diseases Society of America reported on June 29, 2018, that a new HIV acquisition had been found in a person using pre-exposure prophylaxis (PrEP). According to the journal article, a 28-year-old cisgender male in Thailand began using PrEP on March 16, 2016, after being verified HIV negative by a third generation antibody test. However the third generation antibody test available in this case has a window period of three to 12 weeks, with 3% of the population still testing HIV negative after 12 weeks. This is why clinical testing sites use RNA testing whenever possible, as the RNA test from May 13 did show positive for HIV while the third generation antibody test on the same day showed HIV negative.

Published
17 July 2018
From
TheBody PRO
Dolutegravir durable with high rates of viral suppression in people who experienced virological failure with older integrase inhibitors

Antiretroviral regimens containing the integrase inhibitor dolutegravir are durable and achieve high rates of viral suppression in people who experienced virological failure with older integrase

Published
09 July 2018
By
Michael Carter
Transmitted drug resistance now less likely to harm HIV treatment options, US study finds

The rising prevalence of transmitted antiretroviral drug resistance in the United States is unlikely to affect the success of first-line treatment in the future and

Published
19 June 2018
By
Keith Alcorn
Low CD4 count in patients with HIV prolongs influenza viral shedding

HIV-infected individuals with a low CD4 count experienced a longer duration of influenza virus shedding, according to findings published in The Journal of Infectious Diseases.

Published
11 June 2018
From
Healio itj+ (requires free registration)
Computer Models Are Changing How We Craft HIV-AIDS Policies

A computer modeling of AIDS-affected populations of sub-Saharan Africa has recently enabled the World Health Organization (WHO) to identify a cost-effective measure to address the increasing prevalence of drug-resistant HIV in the region.

Published
04 May 2018
From
Healthcare Analytics News
← First12345...38Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.